Literature DB >> 4065190

Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man.

R Padrini, E Barbieri, D Piovan, M Toffoli, A Motta, G P Trevi, M Ferrari.   

Abstract

The plasma levels and myocardial content of verapamil and its metabolites norverapamil, N-dealkylverapamil and N-dealkylnorverapamil were determined in 15 patients with valvular [3] or ischaemic [12] heart disease. The mean myocardial plasma concentration ratio (M/P) was 7.05 for verapamil, 11.45 for norverapamil, 8.93 for N-dealkylverapamil, and 11.33 for N-dealkylnorverapamil, with great interpatient variability. The highest M/P ratios of verapamil were generally found in patients with the lowest plasma levels, suggesting that saturable tissue uptake may occur.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4065190     DOI: 10.1007/BF00607910

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  High-affinity binding sites for [3H] verapamil in cardiac membranes.

Authors:  U L Hulthén; R Landmann; E Bürgisser; F R Bühler
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

Review 2.  Adverse reactions to calcium antagonists.

Authors:  J G Lewis
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

3.  High-performance liquid chromatographic analysis of verapamil. II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil.

Authors:  S R Harapat; R E Kates
Journal:  J Chromatogr       Date:  1980-03-14

4.  Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog.

Authors:  G Neugebauer
Journal:  Cardiovasc Res       Date:  1978-04       Impact factor: 10.787

5.  The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.

Authors:  R G McAllister; E B Kirsten
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

6.  The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration.

Authors:  J A Dominic; D W Bourne; T G Tan; E B Kirsten; R G McAllister
Journal:  J Cardiovasc Pharmacol       Date:  1981 Jan-Feb       Impact factor: 3.105

7.  Pharmacokinetics of verapamil in man.

Authors:  Y Koike; K Shimamura; I Shudo; H Saito
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-04

8.  Plasma concentration--response relationship of verapamil in the treatment of angina pectoris.

Authors:  P Anderson; U Bondesson; C Sylvén; H Aström
Journal:  J Cardiovasc Pharmacol       Date:  1982 Jul-Aug       Impact factor: 3.105

9.  Serum concentration and antihypertensive effect of slow-release verapamil.

Authors:  E Schütz; H R Ha; F R Bühler; F Follath
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

10.  Clinical relevance of verapamil plasma levels in stable angina pectoris.

Authors:  W Frishman; E Kirsten; M Klein; M Pine; S M Johnson; L D Hillis; M Packer; R Kates
Journal:  Am J Cardiol       Date:  1982-11       Impact factor: 2.778

View more
  3 in total

1.  Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.

Authors:  D N John; S Fort; M J Lewis; D K Luscombe
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 2.  Myocardial uptake of drugs and clinical effects.

Authors:  J D Horowitz; A C Powell
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

3.  Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses.

Authors:  L Carosella; P Menichelli; M Alimenti; G Zuccala; A Gemma; A Cocchi; P U Carbonin
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.